7 comments

  • ijustwork 6 minutes ago

    The metabotropic glutamate receptor subtype 5 (mGlu5) is involved in the central mechanism of action of paracetamol (acetaminophen), where the bioactive metabolite AM404 activates the TRPV1 channel–mGlu5 receptor–PLC–DAGL–CB1 receptor signaling cascade in the periaqueductal grey, contributing to its analgesic effect.

  • ear7h an hour ago

    N=32 and

    > We want to start creating a developmental story and start understanding whether the things that we’re seeing are the root of autism or a neurological consequence of having had autism your whole life

      jmward01 40 minutes ago

      Yeah, how many studies are done a year? Random chance is the #1 explanation with that small of a sample size. It doesn't take a degree in stats say that the next thing that needs to be done is to replicate the study a few times before making any claims or searching for any publicity. This subject is so emotional for the families involved that publicizing without more confirmation is a bit irresponsible especially if it is easy to do follow-up studies.

        slashdave 24 minutes ago

        It's a university press release. Hyperbole in practice.

        Wish I could read the paper.

  • NewUser76312 an hour ago

    Interesting indeed. Does such a finding suggest any worthwhile easy-to-try 'treatments' that may help alleviate symptoms?

    I don't know much about the biochemistry here, I assume this is not something like GABA that can be directly supplemented. But maybe there are precursor nutritional and supplemental substances that can help these people upregulate how much of the glutamate molecule in question the body can produce.

      esseph 5 minutes ago

      [delayed]

      wizzwizz4 an hour ago

      There isn't enough information to start doing that, yet. Consider: UV exposure results in sunburn, cellular damage, and increased skin pigmentation. We have medication that reduces skin pigmentation. Should we give it to people who experience chronic sunburn?